In vitro platform using non-human primate stem and primary cells for drug efficacy, safety, gene-manipulation and cell therapy screening, targeting preclinical researchers and drug developers. Reduces and replaces live primate use to accelerate and lower-cost early-stage screening while supporting NAMs and FDA Modernization Act 2.0 compliance.